Thompson, Philip

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine

CAR-T cell therapy researchImmune Cell Function and Interaction

Cited by 2,217

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies

Guièze, R., Liu, V. M., Rosebrock, D., Jourdain, A. A., Hernández-Sánchez, M., Martinez Zurita, A., Sun, J., Ten Hacken, E., Baranowski, K., Thompson, P. A., et al. (2019) · Cancer Cell

Cell death mechanisms and regulationChronic Lymphocytic Leukemia Research

Cited by 361

Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia

Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 135

Pirtobrutinib: a new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders

Thompson, P. A., & Tam, C. (2023) · Blood Journal

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 42